Radiotherapy of human xenograft NSCLC tumors in nude mice with a 90Y-labeled anti-tissue factor antibody

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 3, 2005, Pages 300-309

  Wang, Baiyang ^a   Berger, Marc ^b   Masters, Gregg ^b   Albone, Earl ^b   Yang, Qifeng ^b   Sheedy, Josephine ^b   Kirksey, Yolanda ^b   Grimm, Lisa ^b   Wang, Bo ^b   Singleton, Judith ^b   Soltis, Daniel ^b  

^a BioRexis Pharmaceutical Corporation   (United States)

^b PURDUE PHARMA L P   (United States)

Author keywords

Antibody; NSCLC; Radioimmunotherapy; Tissue factor; Yttrium

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TF278 Y 90; THROMBOPLASTIN; UNCLASSIFIED DRUG; YTTRIUM 90;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURFACE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; ANTIBODIES; ANTIGENS; CARCINOMA, NON-SMALL-CELL LUNG; ENDOCYTOSIS; HUMANS; MICE; MICE, NUDE; RADIATION DOSAGE; THROMBOPLASTIN; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS; YTTRIUM RADIOISOTOPES;

EID: 22344434955     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.300     Document Type: Article

References (30)

1. Nemerson Y. Tissue factor and hemostasis. Blood 1988;71:1.
2. Akashi T, Furuya Y, Ohta S, et al. Tissue factor expression and prognosis in patients with metastatic prostate cancer. Urology 2003;62:1078.
3. Ohta S, Wada H, Nakazaki T, et al. Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res 2002; 22:2991.
4. Shigemori C, Wada H, Matsumoto K, et al. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998;80:894.
5. Lykke J, Nielsen HJ. The role of tissue factor in colorectal cancer. Eur J Surg Oncol 2003;29:417.
6. Koomagi R, Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: Correlation between tissue factor and angiogenesis. Int J Cancer 1998;79:19.
7. Sawada M, Miyake S, Ohdama S, et al. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999;79:472.
8. Contrino J, Hair G, Kreutzer DL, et al. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209.
9. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996;383:73.
10. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer: Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998;152:399.
11. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320.
12. Seto S, Onodera H, Kaido T, et al. Tissue factor expression in human colorectal carcinoma: Correlation with hepatic metastasis and impact on prognosis. Cancer 2000;88:295.
13. Mueller BM, Reisfeld RA, Edgington TS, et al. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 1992;89:11832.
14. Bromberg ME, Konigsberg WH, Madison JF, et al. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92:8205.
15. Ruf W. Tissue factor-dependent signaling in tumor biology. Pathophysiol Haemost Thromb 2003;33(Suppl 1):28.
16. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10:502.
17. Fleck RA, Rao LV, Rapaport SI, et al. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal antihuman tissue factor antibody. Thromb Res 1990;59:421.
18. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA 1999;96:8161.
19. Hu Z, Garen A. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA 2001;98:12180.
20. Chen C, Yang Q, Patel S, et al. Characterization of human tissue factor (TF)-specific monoclonal antibodies prepared using a rapid immunization protocol. Hybridoma Hybridomics 2005;24:78.
21. Lewis MR, Kao JY, Anderson AL, et al. An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA. Bioconj Chem 2001; 12:320.
22. Dadachova E, Chappell LL, Brechbiel MW. Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. Nucl Med Biol 1999;26:977.
23. 131I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. J Nucl Med 2001; 42:509.
24. Mao W, Luis E, Ross S, et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res 2004;64:781.
25. Ong GL, Mattes MJ. Limitations in the use of low pH extraction to distinguish internalized from cell surface-bound radiolabeled antibody. Nucl Med Biol 2000;27:571.
26. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992;70:1194.
27. Cao Y. Antiangiogenic cancer therapy. Semin Cancer Biol 2004;14:139.
28. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118.
29. Chart RVJ. Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy. Adv Drug Deliv Rev 1998;31:89.
30. 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkins' lymphoma. Int J Oncol 1999;15:1017.